Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates

The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor agonism, are currently unavailable. Here, we investigated [68Ga]Ga-DO3A-S01-GCG as a biomark...

Full description

Saved in:
Bibliographic Details
Main Authors: Eriksson, Olof, Velikyan, Irina, Haack, Torsten, Bossart, Martin, Evers, Andreas, Laitinen, Iina, Larsen, Philip J., Plettenburg, Oliver, Takano, Akihiro, Halldin, Christer, Antoni, Gunnar, Johansson, Lars, Pierrou, Stefan, Wagner, Michael
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2020
Subjects:
Online Access:https://hdl.handle.net/10356/142352
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-142352
record_format dspace
spelling sg-ntu-dr.10356-1423522020-11-01T05:26:33Z Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates Eriksson, Olof Velikyan, Irina Haack, Torsten Bossart, Martin Evers, Andreas Laitinen, Iina Larsen, Philip J. Plettenburg, Oliver Takano, Akihiro Halldin, Christer Antoni, Gunnar Johansson, Lars Pierrou, Stefan Wagner, Michael Lee Kong Chian School of Medicine (LKCMedicine) Science::Medicine Positron Emission Tomography (PET) Glucagon Receptor (GCGR) The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor agonism, are currently unavailable. Here, we investigated [68Ga]Ga-DO3A-S01-GCG as a biomarker for GCGR occupancy in liver, the tissue with highest GCGR expression, in non-human primates (NHP) by PET. [68Ga]Ga-DO3A-S01-GCG was evaluated by dynamic PET in NHPs by a dose escalation study design, where up to 67 µg/kg DO3A-S01-GCG peptide mass was co-injected. The test-retest reproducibility of [68Ga]Ga-DO3A-S01-GCG binding in liver was evaluated. Furthermore, we investigated the effect of pre-treatment with acylated glucagon agonist 1-GCG on [68Ga]Ga-DO3A-S01-GCG binding in liver. [68Ga]Ga-DO3A-S01-GCG bound to liver in vivo in a dose-dependent manner. Negligible peptide mass effect was observed for DO3A-S01-GCG doses <0.2 µg/kg. In vivo Kd for [68Ga]Ga-DO3A-S01-GCG corresponded to 0.7 µg/kg, which indicates high potency. The test-retest reproducibility for [68Ga]Ga-DO3A-S01-GCG binding in liver was 5.7 ± 7.9%. Pre-treatment with 1-GCG, an acylated glucagon agonist, resulted in a GCGR occupancy of 61.5 ± 9.1% in liver. Predicted human radiation dosimetry would allow for repeated annual [68Ga]Ga-DO3A-S01-GCG PET examinations. In summary, PET radioligand [68Ga]Ga-DO3A-S01-GCG is a quantitative biomarker of in vivo GCGR occupancy. Published version 2020-06-19T05:45:17Z 2020-06-19T05:45:17Z 2019 Journal Article Eriksson, O., Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., . . . Wagner, M. (2019). Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates. Scientific Reports, 9(1), 14960-. doi:10.1038/s41598-019-51530-0 2045-2322 https://hdl.handle.net/10356/142352 10.1038/s41598-019-51530-0 31628379 2-s2.0-85073590810 1 9 en Scientific Reports © 2019 The Author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Te images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Medicine
Positron Emission Tomography (PET)
Glucagon Receptor (GCGR)
spellingShingle Science::Medicine
Positron Emission Tomography (PET)
Glucagon Receptor (GCGR)
Eriksson, Olof
Velikyan, Irina
Haack, Torsten
Bossart, Martin
Evers, Andreas
Laitinen, Iina
Larsen, Philip J.
Plettenburg, Oliver
Takano, Akihiro
Halldin, Christer
Antoni, Gunnar
Johansson, Lars
Pierrou, Stefan
Wagner, Michael
Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
description The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor agonism, are currently unavailable. Here, we investigated [68Ga]Ga-DO3A-S01-GCG as a biomarker for GCGR occupancy in liver, the tissue with highest GCGR expression, in non-human primates (NHP) by PET. [68Ga]Ga-DO3A-S01-GCG was evaluated by dynamic PET in NHPs by a dose escalation study design, where up to 67 µg/kg DO3A-S01-GCG peptide mass was co-injected. The test-retest reproducibility of [68Ga]Ga-DO3A-S01-GCG binding in liver was evaluated. Furthermore, we investigated the effect of pre-treatment with acylated glucagon agonist 1-GCG on [68Ga]Ga-DO3A-S01-GCG binding in liver. [68Ga]Ga-DO3A-S01-GCG bound to liver in vivo in a dose-dependent manner. Negligible peptide mass effect was observed for DO3A-S01-GCG doses <0.2 µg/kg. In vivo Kd for [68Ga]Ga-DO3A-S01-GCG corresponded to 0.7 µg/kg, which indicates high potency. The test-retest reproducibility for [68Ga]Ga-DO3A-S01-GCG binding in liver was 5.7 ± 7.9%. Pre-treatment with 1-GCG, an acylated glucagon agonist, resulted in a GCGR occupancy of 61.5 ± 9.1% in liver. Predicted human radiation dosimetry would allow for repeated annual [68Ga]Ga-DO3A-S01-GCG PET examinations. In summary, PET radioligand [68Ga]Ga-DO3A-S01-GCG is a quantitative biomarker of in vivo GCGR occupancy.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Eriksson, Olof
Velikyan, Irina
Haack, Torsten
Bossart, Martin
Evers, Andreas
Laitinen, Iina
Larsen, Philip J.
Plettenburg, Oliver
Takano, Akihiro
Halldin, Christer
Antoni, Gunnar
Johansson, Lars
Pierrou, Stefan
Wagner, Michael
format Article
author Eriksson, Olof
Velikyan, Irina
Haack, Torsten
Bossart, Martin
Evers, Andreas
Laitinen, Iina
Larsen, Philip J.
Plettenburg, Oliver
Takano, Akihiro
Halldin, Christer
Antoni, Gunnar
Johansson, Lars
Pierrou, Stefan
Wagner, Michael
author_sort Eriksson, Olof
title Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
title_short Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
title_full Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
title_fullStr Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
title_full_unstemmed Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
title_sort assessment of glucagon receptor occupancy by positron emission tomography in non-human primates
publishDate 2020
url https://hdl.handle.net/10356/142352
_version_ 1683494131006963712